IGF::OT::IGF Retrospective Tumor Characterization Analysis

通过利用从NCI国家临床试验网络（NCTN）计划和/或NCI社区肿瘤学研究计划（NCORP）进行的已完成试验（具有可用结局结果）中收集的生物标本，并将其储存在相关的生物标本库中，分子特征分析预测治疗反应（MP2 PRT）计划将实施蓝丝带小组的建议。将在本任务指令的支持下，根据NCI指定的多学科审查流程，选择从NCTN/NCORP组征集的具有存档生物标本的适当研究项目进行分子表征。任务指令将支持存档生物标本分子表征的综合方法（例如，肿瘤组织/正常组织、全血、血浆、血清），对分子表征数据与试验结果数据的综合分析，包括预测和预后建模，以及通过将结果存入NCI基因组数据共享区来提供结果的数据共享（以及适当时，由适当的NCTN/NCORP小组将临床试验数据存款在NCTN/NCORP数据档案中）。

The Molecular Profiling to Predict Response to Treatment (MP2PRT) initiative will implement the Blue-Ribbon Panel’s recommendation by leveraging biospecimens collected from completed trials (with available outcome results) that were conducted by the NCI National Clinical Trials Network (NCTN) Program and/or the NCI Community Oncology Research Program (NCORP) and stored in their associated biospecimen repositories. Appropriate research projects solicited from the NCTN/NCORP Groups with archived biospecimens will be selected for molecular characterization under an NCI-designated, multidisciplinary review process with support from this Task Order. The Task Order will support an integrated approach to the molecular characterization of the archived biospecimens (e.g., tumor tissue/normal tissue, whole blood, plasma, serum) from the selected NCTN or NCORP trials, the comprehensive analysis of the molecular characterization data with trial outcome data including predictive and prognostic modeling, and the provision of data sharing of results by depositing the results in the NCI Genomic Data Commons (as well as having the appropriate NCTN/NCORP Group deposit the clinical trial data in the NCTN/NCORP Data Archive, if appropriate).